NL-OMON28300已完成不适用
A phase II study of gefitinib and fulvestrant in patients with advanced, EGFR mutated non-small cell lung cancer pretreated with reversible EGFR tyrosine kinase inhibitors.
VU University Medical Center0 个研究点目标入组 48 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 48
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Histologically or cytologically confirmed NSCLC locally advanced and metastatic disease stage IIIB and IV, that have an activating EGFR mutation, progressive on treatment with gefitinib or erlotinib. Patients with unknown mutation status that have exhibited a response to these agents or stable disease for at least 6 months while on treatment with gefitinib or erlotinib are also eligible;
- •2. At least one unidimensionally measurable lesion meeting RECIST 1.1 criteria;
排除标准
- •1. Pregnant or lactating women;
- •2. Patients who are poor medical risks because of non-malignant disease as well as those with active uncontrolled infection;
研究者
相似试验
撤回
2 期
A phase II study of gefitinib and fulvestrant in patients with advanced EGFR mutated non small cell lung cancer pretreated with reversible EGFR tyrosine kinase inhibitorsadvanced stage non-small cell lung cancermetastatic non-small cell lung cancer1003866610029107NL-OMON37908Vrije Universiteit Medisch Centrum48
进行中（未招募）
不适用
Treatment with gefitinib and fulvestrant in patients with non-small cell lungcancerPatients with pathologically documented NSCLC with an EGFR mutation, who failed previous treatment with reversible EGFR TKI’s (gefitinib or erlotinib).EUCTR2012-000345-12-NLVU Medical Center
已完成
不适用
A phase II study of gefitinib as first-line treatment for elderly patients with advanced lung adenocarcinoma who have active EGFR mutationslung adenocarcinomaJPRN-UMIN000002783agano lung cancer study meeting15
已完成
2 期
A phase II study of first-line gefitinib for advanced and recurrent EGFR mutation positivenon-small cell lung cancerwith high-risk factorsnon-small cell lung cancerJPRN-UMIN000004822Kanagawa Cancer Center37
已完成
2 期
phase II study of gefitinib as a first-line therapy in elderly patients with lung adenocarcinoma.JPRN-C000000136West Japan Oncology Group30